- Open Access
Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin
© Molhoek et al; licensee BioMed Central Ltd. 2005
- Received: 12 August 2005
- Accepted: 28 October 2005
- Published: 28 October 2005
Targeted inhibition of protein kinases is now acknowledged as an effective approach for cancer therapy. However, targeted therapies probably have limited success because cancer cells have alternate pathways for survival and proliferation thereby avoiding inhibition. We tested the hypothesis that combination of targeted agents would be more effective than single agents in arresting melanoma cell proliferation.
We evaluated whether BAY43-9006, an inhibitor of the B-Raf kinase, and rapamycin, an inhibitor of the mTOR kinase, would inhibit serum-stimulated proliferation of human melanoma cell lines, either alone or in combination. Proliferation was measured by quantitating melanoma cell numbers with a luciferase for ATP. Phosphorylation of proteins downstream of targeted kinase(s) was assayed by immunoblots. Statistical significance was determined with the Student-T test. Isobologram analysis was performed to distinguish additive versus synergistic effects of combinations of drugs.
Serum-stimulated proliferation of multiple human melanoma cell lines was inhibited by BAY43-9006 and by rapamycin. Melanoma cells containing the B-Raf mutation V599E were more sensitive than cells with wild-type B-raf to 10 nM doses of both BAY43-9006 and rapamycin. Regardless of B-Raf mutational status, the combination of low dose rapamycin and BAY43-9006 synergistically inhibited melanoma cell proliferation. As expected, rapamycin inhibited the phosphorylation of mTOR substrates, p70S6K and 4EBP1, and BAY43-9006 inhibited phosphorylation of ERK, which is dependent on B-Raf activity. We also observed unexpected rapamycin inhibition of the phosphorylation of ERK, as well as BAY43-9006 inhibition of the phosphorylation of mTOR substrates, p70S6K and 4EBP1.
There was synergistic inhibition of melanoma cell proliferation by the combination of rapamycin and BAY 43-9006, and unexpected inhibition of two signaling pathways by agents thought to target only one of those pathways. These results indicate that combinations of inhibitors of mTOR and of the B-raf signaling pathways may be more effective as a treatment for melanoma than use of either agent alone.
In human cancers, mutant oncogenes are frequently associated with disease progression . Thus, there is a need for development of effective therapies that can slow progression of solid tumors by blocking the action of those oncogenes. Cancer therapy has undergone a paradigm shift based on the therapeutic effectiveness of imatinib mesylate (Gleevec). This drug was designed as a specific inhibitor of the BCR-ABL oncogene protein tyrosine kinase, known to be responsible for chronic myeloid leukemia (CML) cells . The therapeutic effectiveness of Gleevec and relative absence of detrimental side-effects has made it a model for the development of an array of new therapeutic agents targeted to inhibit signal transduction enzymes, especially protein kinases.
The recent discovery that 60–70% of human melanomas have activating mutations in B-Raf (with 80% of these mutations caused by a single substitution V599E) make this protein kinase an especially promising target for inhibition [3, 4]. Indeed, lead compounds have been produced and tested, and currently are working their way through clinical trials. One example is BAY43-9006 (aka: sorafenib, N-(3-trifluoromethyl-4-chlorophenyl)-N'-(4-(2-methylcarbamoyl pyridin-4-yl)oxyphenyl)urea), an investigational compound, currently in phase II and III clinical trials, designed to inhibit both B-Raf and C-Raf kinases [5, 6]. B-Raf is a component of a cell signaling pathway which includes the upstream activator of Raf, called Ras, and the direct substrate of Raf, called MEK1/2 and the MEK substrate ERK1/2 . B-Raf phosphorylates MEK1 and MEK2 on Ser217 and Ser221, which activates it to dual phosphorylate ERKs, at Thr202/Tyr204 for human ERK1 and Thr185/Tyr187 for human ERK2 [8, 9]. Mutations in RAF which cause constitutive activation of Raf kinase are thought to promote events leading to carcinogenesis. Pre-clinical and early phase I studies have suggested that BAY 43-9006 may be of therapeutic value not only in human tumors containing ras gene mutations, but also in tumors over-expressing growth factor receptors that activate the Ras/ERK pathway . However, these studies have not addressed the effects of BAY 43-9006 in combination with any other kinase inhibitors.
Another molecular pathway commonly mutated (30–60%) in melanomas involves loss of the PTEN tumor suppressor gene, which can lead to constitutive activation of the mTOR kinase signaling pathway [11–13]. Inhibition of mTOR kinase is feasible with the macrolide natural product rapamycin (aka: sirolimus, RAPA, Rapamune, AY-22989, and NSC-226080). Rapamycin is an FDA-approved agent used as immunosuppressive therapy post organ transplant [14, 15]. More recent clinical application of rapamycin has been with coated stents to suppress the neo-intima formation during restenosis in response to balloon angioplasty . The action of rapamycin is understood to involve binding to the receptor protein FKBP12; this drug-protein complex binds to the mTOR protein kinase and interferes with phosphorylation of two well-recognized downstream targets, p70S6K (p70 ribosomal S6 kinase) and 4EBP1 (aka: 4E binding protein 1, eukaryotic translation initiation factor 4E binding protein, and PHAS-1) . An appreciation of the potent inhibition of cell growth and protein synthesis, as well as cell cycle arrest, imposed by rapamycin led to testing of its derivatives, in particular CCI-779, as cytostatic agents, especially for various cancers refractory to other forms of cancer chemotherapy [18–20]. Pharmacokinetic analysis revealed that CCI-779 was progressively converted into rapamycin, its main metabolite, beginning as early as 15 minutes after infusion of the drug , therefore, we used rapamycin in our studies.
Our interest is in combining targeted agents for these pathways in an effort to determine if such treatments will be effective in the treatment of melanoma. We hypothesized that the combination of multiple targeted therapeutic agents would result in enhanced inhibition of melanoma cell proliferation compared to either drug alone, because of synergy between effects on two pathways. Here we show that serum-stimulated melanoma cell proliferation is inhibited by either rapamycin or BAY43-9006, with B-Raf V599E mutants showing an increased sensitivity to each drug at 10 nM compared to melanoma cells with wild-type B-Raf. Each of these drugs inhibited the serum-stimulated phosphorylation of known Raf and mTOR substrates. What was unexpected was that each of the drugs inhibited phosphorylation in both the Raf and mTOR pathways, suggesting there was interdependence or cross-talk between these pathways in melanoma cells. Furthermore, the combination of rapamycin with BAY43-9006 was synergistic compared to either drug alone at inhibiting proliferation of wild-type B-Raf and V599E mutant B-Raf melanoma cell lines.
Reagents and Inhibitors
The MEK1/2 inhibitor U0126 (Catalog # 662005) and BAY43-9006 (Catalog # 553011) were purchased from Calbiochem, and stock solutions were made in DMSO. Rapamycin (R-5000) was purchased from LC Laboratories and a stock solution was made in DMSO.
Cell Proliferation Assays
Anti-p70S6 Kinase, clone SB20 Antibody (Catalog # 05-781, used at 1:8000) was purchased from Upstate. 4E-BP1 Antibody (Catalog #9452, used at 1:500) was purchased from Cell Signaling. GAPDH Antibody (Catalog # MAB374, used at 1:500) was purchased from Chemicon International. Anti-phospho MAP Kinase (ERK1/2), clone 12D4 antibody (Catalog # 05-481, used at 1:500) was purchased from Upstate. Anti-MAP Kinase 2/ERK2 antibody (Catalog #06-333, used at 1:500) was also purchased from Upstate. Phospho-MEK1/2 (Ser217/221) Antibody (Catalog#2354S, used at 1:1000) was purchased from Cell Signaling. Anti-Mouse IgG, peroxidase-linked species-specific whole antibody from sheep, secondary antibody (Catalog #NA931, used at 1:5000) was purchased from Amersham Biosciences. Anti-rabbit IgG, peroxidase-linked species-specific whole secondary antibody from donkey (Catalog # NA934, used at 1:5000) was also purchased from Amersham Biosciences.
To assess whether a combination dose of rapamycin and BAY43-9006 is synergistic or simply additive, a focused isobologram method was used as described previously . An IC70 was selected, and these doses of each drug alone were plotted as the ordinate and abscissa in a Cartesian log-log plot. The straight line connecting these IC70 values is the locus of points (dose pairs) that produce a simply additive combination. In an isobologram, the IC70 dose pairs for two drugs together which fall on the line indicate an additive effect. Points above this line indicate antagonism, and points below the line indicate synergism.
All of the research involving human subjects was approved by the University of Virginia's IRB (Human Investigation Committee) in accordance with assurances filed with and approved by the Department of Health and Human Services. Informed consent was obtained from all of the study participants.
Proliferation of melanoma cells expressing wild-type and V599E mutant B-Raf
We examined the serum-dependent proliferation of various human melanoma cell lines. Figure 1 A is a growth curve for the VMM18 cell line, which is representative of the growth curves generated for each of the cell lines from a collection of human melanomas (Table 1). Cell proliferation was determined by the number of cells at 0, 4, 8, 16, 24, 48, and 72 hours, quantitated using the Cell Titer 96 Aqueous (Promega Corporation, Madison, WI) assay which measures reduction of MTS (a novel tetrazolium compound). These human melanoma cell lines proliferated even in limiting serum (0.5%). However, all showed higher rates of proliferation ~ 2-fold in the presence of 5% serum.
We could detect activation of the mTOR and ERK signaling pathways in proliferating melanoma cells. Shown in Figure 1 B is a Western blot detecting the phosphorylation of the mTOR substrate, 4EBP1, from 3 different melanoma cell lines grown in the presence of either 5% or 0.5% serum. The phosphorylation of 4EBP1 has previously been demonstrated to retard migration in SDS-PAGE , seen as the upper band in the doublet in the even numbered lanes (Figure 1B). Shown in Figure 1 C is a Western blot detecting both the dual phosphorylated (activated) form of ERK, as well as total ERK protein in three different melanoma cell lines grown in 5% or 0.5% serum. The quantitation of the relative phosphorylation of ERK relative to total ERK is shown between the blots, demonstrating about a two-fold increase in phosphorylation. The phosphorylation of ERK paralleled the relative increase in proliferation for each of these cell lines.
BAY43-9006 and rapamycin inhibit proliferation of melanoma cells
Among the melanoma cell lines, there was a significant difference in the amount of inhibition at 10 nM BAY43-9006 or rapamycin. We observed that melanoma cell lines that contain the V599E mutation in B-Raf (VMM5A and VMM18) were more sensitive to BAY43-9006 and to rapamycin, compared to cell lines with wild-type B-Raf (VMM39). This difference in growth inhibition was observed in two additional cell lines, one wild-type (DM122) and one V599E (VMM12). Therefore, nanomolar concentrations of either BAY43-9006 or rapamycin inhibit the proliferation of melanoma cells, whether or not they have mutated B-Raf.
Combining Rapamycin with BAY43-9006 synergistically inhibits serum-dependent proliferation of melanoma cells
Rapamycin and BAY43-9006 inhibit phosphorylation of proteins in the mTOR signaling pathway in melanoma cells
Melanoma cells were treated with rapamycin and BAY 43-9006, either singly or in combination, for one hour, and protein phosphorylation was examined by Western blot analysis 24 hours later. Rapamycin is an inhibitor of mTOR kinase and reduces phosphorylation of its substrates, p70S6K and 4EBP1 . BAY 43-9006 is a chemical inhibitor of B-Raf kinase and reduces phosphorylation of MEK and ERK [26, 27]. VMM18 melanoma cells grown in the presence of 5% serum had enhanced phosphorylation of p70S6K and 4EBP1 (Figure 4, lane 2) relative to cells grown in the absence of serum (Figure 4, PBS, lane 1). The phosphorylation of p70S6K and 4EBP1 retards migration in SDS-PAGE. Antibodies to these proteins were used to show all the protein and therefore enable evaluation of the fraction phosphorylated under different conditions. Treatment of VMM18 melanoma cells with a 10 nM dose of rapamycin inhibited the serum-stimulated phosphorylation of p70S6K and 4EBP1 (Figure 4, lane 3). Parallel treatment of VMM18 melanoma cells with a 10 nM dose of BAY43-9006 unexpectedly inhibited serum-stimulated phosphorylation of p70S6K and 4EBP1 (Figure 4, lane 4). There is not a well-documented requirement of Raf-MEK-ERK activity for the phosphorylation of mTOR substrates p70S6K and 4EBP1. Combination treatment with a 10 nM dose of rapamycin plus a 10 nM dose of BAY43-9006 blocked phosphorylation of p70S6K and 4EBP1 as effectively as either drug alone (Figure 4, lane 5). Thus, even though cell proliferation was suppressed more effectively by this combination of drugs, this was not reflected in a detectable further decrease in phosphorylation of the mTOR target proteins p70S6K and 4EBP1. As an additional control, we treated VMM18 melanoma cells with U0126, a MEK inhibitor, which blocked serum-stimulated phosphorylation of both p70S6K and 4EBP1 (Figure 4, lane 6). This result showed that MEK/ERK activities contribute to phosphorylation of p70S6K and 4EBP1.
We noted that total 4EBP1 in cells treated with a combination of rapamycin plus BAY43-9006, or with U0126, was lower relative to untreated cells or cells treated with either rapamycin or BAY43-9006 alone. Equal recovery of other proteins from the cells was demonstrated by immunoblotting both for p70S6K and for GAPDH, used as a loading control. We do not understand the basis for the reduced recovery of 4EBP1, but it did not seem to depend simply on the phosphorylation state because phosphorylation was blocked with the single drug treatments, without change in the level of the 4EBP1 protein.
Rapamycin and BAY43-9006 inhibit phosphorylation of proteins in the B-Raf-MEK-ERK signaling pathway in melanoma cells
In VMM18 melanoma cells, the dual phosphorylation (Tyr/Thr) of ERK was 9-fold higher in cells grown in 5% serum relative to cells grown in the absence of serum (Figure 5, lanes 2 versus 1). There also was an increased level in the dual phosphorylation (Ser217/221) of MEK (not shown). Treatment of VMM18 melanoma cells with a 10 nM dose of BAY 43-9006 produced a 75% decrease in the dual phosphorylation of ERK (Figure 5, lane 4) and reduced the phosphorylation of MEK below detection levels (not shown). These results were consistent with the inhibition of B-Raf by BAY43-9006. On the other hand, when VMM18 melanoma cells were treated with a 10 nM dose of rapamycin, the dual phosphorylation of ERK was reduced by about half (Figure 5, lane 3). Our interpretation of this result is that mTOR activity is required to maintain the phosphorylation of ERK in melanoma cells. Combination treatment of a 10 nM dose of rapamycin plus a 10 nM dose of BAY 43-9006 reduced the phosphorylation of ERK to a level even below that seen in cells grown in the absence of serum (Figure 5, lane 5). This inhibition of ERK phosphorylation by combination of rapamycin and BAY43-9006 was as effective as inhibition of MEK by the U0126 compound (Figure 5, compare lanes 5 and 6).
New cancer treatments involve directly targeting enzymes essential for the growth and proliferation of cancer cells. The mTOR pathway regulates cell growth, and the Raf/MEK/ERK pathway is critical for cell proliferation. Activating mutations in B-Raf have been found in 60–70% of human melanomas, making B-Raf a potential target for small molecule inhibitors as therapy [3, 4, 11, 28]. Indeed, new drugs such as BAY43-9006 have been developed as selective inhibitors of B-Raf and are currently in Phase II clinical trials . Inhibition of mTOR by rapamycin has been standard treatment for immunosuppression following organ transplant , and the rapamycin derivative CCI-779 is now being clinically tested as a cancer chemotherapy [18–20]. Thus, B-Raf and mTOR are acknowledged targets for anti-proliferative therapy .
Current knowledge suggests that B-Raf and mTOR protein kinases operate in separate signaling pathways. The B-Raf kinase is activated by GTP-Ras in response to growth factors and phosphorylates MEK, which in turn activates ERK to phosphorylate downstream targets such as kinases and transcription factors that promote cell division . The mTOR kinase responds to both nutrient and growth factor signals to activate p70S6K and 4EBP1 to increase protein translation as part of a cell growth response . Increase in cell growth (size) is a pre-requisite for cell proliferation. Because the B-Raf and mTOR pathways are thought to operate in parallel, we hypothesized that combined inhibition of these kinases would be effective in blocking cell growth and cell proliferation. Though our results with multiple melanoma cell lines support that hypothesis, they also gave some unexpected results.
Human tumors deficient in PTEN have activated Akt, and are especially sensitive to mTOR inhibitors . However, pharmacogenomic profiling indicates that melanomas are not, in general, PTEN deficient and therefore would be unresponsive to mTOR inhibitors. Results from a phase II trial using CCI-779 alone showed only one response among 33 observed patients . These data suggest that CCI-779 is not sufficiently active in melanoma as a single agent. However, our data show that melanoma cell proliferation is effectively inhibited in vitro by low doses of rapamycin. Together, these findings argue against use of CCI-779 as a single agent, but support investigation of mTOR inhibitors as part of combination therapy for treatment of patients with malignant melanoma.
With regards to B-Raf, recent structural studies have shown that BAY43-9006 interacts with an inactive conformation of B-Raf . In biochemical assays, the kinase activity of V599E B-Raf is less sensitive to inhibition by BAY43-9006 than wild-type B-Raf, suggesting that melanomas with the B-Raf V599E mutation might be resistant to the effects of this drug . However, in the present study, proliferation of the human melanoma cells was inhibited by BAY43-9006, and at a dose of 10 nM, the cells that contained mutated B-Raf V599E were more sensitive than cells with wild-type B-Raf. In clinical studies with BAY43-9006 plus chemotherapy, objective tumor regressions were more common in patients who had wild-type B-raf . The findings of the current report support continued investigation of BAY43-9006 for treatment of patients with melanoma, and suggest that clinical effects observed may be due to some effects that are independent of B-raf kinase activity.
We found that multiple human melanoma cell lines proliferated in culture at different relative rates in the absence of serum and that the addition of serum to the medium doubled the rate of proliferation. Thus, we could use the consistent serum response to compare cell growth and proliferation with a variety of melanoma cell lines. At concentrations in the nanomolar range, we observed dose-dependent inhibition of cell proliferation by either rapamycin or BAY43-9006. In every cell line examined, combination of BAY43-9006 and rapamycin produced synergistic inhibition of cell proliferation compared to either drug alone. This suggests that administration of a combination of an mTOR inhibitor (rapamycin or CCI-779) and BAY43-9006 could be an especially effective approach to therapy of melanoma.
Our results indicate that rapamycin and BAY43-9006 inhibit their cognate targets in melanoma cells (mTOR and B-Raf respectively), as well as downstream effectors thought to be in other pathways, providing evidence for cellular cross-talk between the different signaling pathways studied. Specifically, we found that BAY43-9006 inhibited serum-stimulated phosphorylation of p70S6K and 4EBP1, and rapamycin blocked serum-stimulated phosphorylation of ERK. Previously published results have suggested interdependence between mTOR and Raf-MEK-ERK signaling [35–40]. In vascular smooth muscle cells under hyperglycemic conditions (25 mM versus 5 mM glucose), inhibition of PI3K with LY294002 or inhibition of mTOR by rapamycin reduced the level of ERK Tyr-phosphorylation . In cardiomyocytes, PKC-dependent activation of mTOR and p70S6K was inhibited by U0126, implicating a requirement for MEK . Rapamycin inhibited the FGF-2 induced proliferation of two different small cell lung cancer lines (SCLC), whereas PD098059 inhibited one and not the other . Combination of rapamycin and PD098059 was not tested. In proximal tubular epithelial cells, insulin-activated phosphorylation of 4EBP1 could be inhibited by PD098059, suggesting a requirement for MAPK . Another report shows that following hypertonic stress, HEK 293 cells show increase in protein synthesis, and simultaneous inhibition of both mTOR and ERK was required to prevent de novo translation .
Since there appears to be cross-talk between mTOR and Raf-MEK-ERK pathways, it might be expected that combination therapy with rapamycin and BAY43-9006 might simply be additive. To our knowledge, the effects of combining inhibitors of these two pathways on proliferation of melanoma cells had not previously been examined. However, studies are in development for such combination therapies in human clinical trials, sponsored by the Clinical Trials Evaluation Program (CTEP) of the NIH. In the present study, we found that the combination of inhibitors synergistic for inhibition of melanoma cell proliferation.
Cancer cells may be dependent on particular oncogenes for cell growth, which renders them sensitive to drugs that inhibit these protein targets. Under these circumstances, single chemical inhibitors are efficacious, such as Gleevec inhibition of BCR-ABL in CML . However, in a number of different cancers, single drug targeted therapy is only effective in about half of the patients . These cancer cells utilize either alternate pathways or compensatory mechanisms to evade inhibition. Under these circumstances, combination therapy that inhibits different pathways may be especially effective. Our results show synergistic inhibition of cell proliferation with drugs against different pathways. Further, we exposed effects on pathways not thought to be targeted by agents currently used in the clinic. Because a combination of rapamycin and BAY43-9006 is more effective at inhibiting melanoma cell proliferation than either drug alone, further studies of this combination in animal models and clinical trials deserve to be examined.
We thank the members of the Slingluff laboratory and Drs. John Lawrence, Christopher Thomas and Yukiko Misawa for helpful discussions. We also thank Dr. Tom Sturgill for the use of his luminometer in our cell proliferation assays. This work was partly supported by grant CA77584 to Dr. David L. Brautigan from USPHS NCI and partly supported by funds from the Harrison Foundation to the University of Virginia Cancer Center and Dr. Craig L. Slingluff, Jr. Support was also provided by the NIH/NCI grant R01 CA57653 (to CLS) and the University of Virginia Cancer Center Support Grant (NIH/NCI P30 CA44579).
- Rodenhuis S: ras and human tumors. Semin Cancer Biol. 1992, 3: 241-247.PubMedGoogle Scholar
- Shah NP, Sawyers CL: Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene. 2003, 22: 7389-7395. 10.1038/sj.onc.1206942.View ArticlePubMedGoogle Scholar
- Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA: Mutations of the BRAF gene in human cancer. Nature. 2002, 417: 949-954. 10.1038/nature00766.View ArticlePubMedGoogle Scholar
- Pollock PM, Meltzer PS: A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell. 2002, 2: 5-7. 10.1016/S1535-6108(02)00089-2.View ArticlePubMedGoogle Scholar
- Tuveson DA, Weber BL, Herlyn M: BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell. 2003, 4: 95-98. 10.1016/S1535-6108(03)00189-2.View ArticlePubMedGoogle Scholar
- Ahmad T, Eisen T: Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res. 2004, 10: 6388S-92S. 10.1158/1078-0432.CCR-040028.View ArticlePubMedGoogle Scholar
- Roux PP, Blenis J: ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev. 2004, 68: 320-344. 10.1128/MMBR.68.2.320-344.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Hartkamp J, Troppmair J, Rapp UR: The JNK/SAPK activator mixed lineage kinase 3 (MLK3) transforms NIH 3T3 cells in a MEK-dependent fashion. Cancer Res. 1999, 59: 2195-2202.PubMedGoogle Scholar
- Burack WR, Sturgill TW: The activating dual phosphorylation of MAPK by MEK is nonprocessive. Biochemistry. 1997, 36: 5929-5933. 10.1021/bi970535d.View ArticlePubMedGoogle Scholar
- Hotte SJ, Hirte HW: BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr Pharm Des. 2002, 8: 2249-2253. 10.2174/1381612023393053.View ArticlePubMedGoogle Scholar
- Krasilnikov M, Ivanov VN, Dong J, Ronai Z: ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene. 2003, 22: 4092-4101. 10.1038/sj.onc.1206598.View ArticlePubMedGoogle Scholar
- Sansal I, Sellers WR: The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004, 22: 2954-2963. 10.1200/JCO.2004.02.141.View ArticlePubMedGoogle Scholar
- Xu G, Zhang W, Bertram P, Zheng XF, McLeod H: Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol. 2004, 24: 893-900.PubMedGoogle Scholar
- Morris RE, Wu J, Shorthouse R: A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. Transplant Proc. 1990, 22: 1638-1641.PubMedGoogle Scholar
- Chiaramonte S, Dissegna D, Ronco C: Monitoring of immunosuppressive therapy in renal transplanted patients. Contrib Nephrol. 2005, 146: 73-86.PubMedGoogle Scholar
- Regar E, Sianos G, Serruys PW: Stent development and local drug delivery. Br Med Bull. 2001, 59: 227-248. 10.1093/bmb/59.1.227.View ArticlePubMedGoogle Scholar
- Chan S: Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer. 2004, 91: 1420-1424. 10.1038/sj.bjc.6602162.PubMed CentralView ArticlePubMedGoogle Scholar
- Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004, 22: 909-918. 10.1200/JCO.2004.08.185.View ArticlePubMedGoogle Scholar
- Peralba JM, DeGraffenried L, Friedrichs W, Fulcher L, Grunwald V, Weiss G, Hidalgo M: Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients. Clin Cancer Res. 2003, 9: 2887-2892.PubMedGoogle Scholar
- Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, Leister C, Korth-Bradley J, Hanauske A, Armand JP: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004, 22: 2336-2347. 10.1200/JCO.2004.08.116.View ArticlePubMedGoogle Scholar
- Brinckerhoff LH, Kalashnikov VV, Thompson LW, Yamshchikov GV, Pierce RA, Galavotti HS, Engelhard VH, Slingluff CLJ: Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int J Cancer. 1999, 83: 326-334. 10.1002/(SICI)1097-0215(19991029)83:3<326::AID-IJC7>3.0.CO;2-X.View ArticlePubMedGoogle Scholar
- Kittlesen DJ, Thompson LW, Gulden PH, Skipper JC, Colella TA, Shabanowitz J, Hunt DF, Engelhard VH, Slingluff CLJ: Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. J Immunol. 1998, 160: 2099-2106.PubMedGoogle Scholar
- Huntington JT, Shields JM, Der CJ, Wyatt CA, Benbow U, Slingluff CLJ, Brinckerhoff CE: Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol Chem. 2004, 279: 33168-33176. 10.1074/jbc.M405102200.View ArticlePubMedGoogle Scholar
- Tallarida RJ: Drug synergism: its detection and applications. J Pharmacol Exp Ther. 2001, 298: 865-872.PubMedGoogle Scholar
- Lehman JA, Calvo V, Gomez-Cambronero J: Mechanism of ribosomal p70S6 kinase activation by granulocyte macrophage colony-stimulating factor in neutrophils: cooperation of a MEK-related, THR421/SER424 kinase and a rapamycin-sensitive, m-TOR-related THR389 kinase. J Biol Chem. 2003, 278: 28130-28138. 10.1074/jbc.M300376200.View ArticlePubMedGoogle Scholar
- Hilger RA, Kredtke S, Scheulen ME, Seeber S, Strumberg D: Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006. Int J Clin Pharmacol Ther. 2004, 42: 648-649.View ArticlePubMedGoogle Scholar
- Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S: Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors. J Clin Oncol. 2004Google Scholar
- Erhardt P, Schremser EJ, Cooper GM: B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol. 1999, 19: 5308-5315.PubMed CentralView ArticlePubMedGoogle Scholar
- Dancey J, Sausville EA: Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov. 2003, 2: 296-313. 10.1038/nrd1066.View ArticlePubMedGoogle Scholar
- Smalley KS: A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?. Int J Cancer. 2003, 104: 527-532. 10.1002/ijc.10978.View ArticlePubMedGoogle Scholar
- Bjornsti MA, Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004, 4: 335-348. 10.1038/nrc1362.View ArticlePubMedGoogle Scholar
- Margolin KA, Longmate J, Baratta T, Synold T, Weber J, Gajewski T, Quirt I, Christensen S, Doroshow JH: CCI-779 in metastatic melanoma: A phase II trial of the California Cancer Consortium. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004, Vol 22, No 14S (July 15 Supplement): Abstract No. 7523-Google Scholar
- Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004, 116: 855-867. 10.1016/S0092-8674(04)00215-6.View ArticlePubMedGoogle Scholar
- Flaherty KT BMSLTDLRJSBLCDWBODPJ: Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J Clin Oncol. 2004, 22: 7507-Google Scholar
- Campbell M, Allen WE, Sawyer C, Vanhaesebroeck B, Trimble ER: Glucose-potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk between the PI3K and MAPK signaling pathways. Circ Res. 2004, 95: 380-388. 10.1161/01.RES.0000138019.82184.5d.View ArticlePubMedGoogle Scholar
- Iijima Y, Laser M, Shiraishi H, Willey CD, Sundaravadivel B, Xu L, McDermott PJ, Kuppuswamy D: c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells. J Biol Chem. 2002, 277: 23065-23075. 10.1074/jbc.M200328200.View ArticlePubMedGoogle Scholar
- Pardo OE, Arcaro A, Salerno G, Tetley TD, Valovka T, Gout I, Seckl MJ: Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells. Oncogene. 2001, 20: 7658-7667. 10.1038/sj.onc.1204994.View ArticlePubMedGoogle Scholar
- Bhandari BK, Feliers D, Duraisamy S, Stewart JL, Gingras AC, Abboud HE, Choudhury GG, Sonenberg N, Kasinath BS: Insulin regulation of protein translation repressor 4E-BP1, an eIF4E-binding protein, in renal epithelial cells. Kidney Int. 2001, 59: 866-875. 10.1046/j.1523-1755.2001.059003866.x.View ArticlePubMedGoogle Scholar
- Naegele S, Morley SJ: Molecular cross-talk between MEK1/2 and mTOR signaling during recovery of 293 cells from hypertonic stress. J Biol Chem. 2004, 279: 46023-46034. 10.1074/jbc.M404945200.View ArticlePubMedGoogle Scholar
- Lehman JA, Gomez-Cambronero J: Molecular crosstalk between p70S6k and MAPK cell signaling pathways. Biochem Biophys Res Commun. 2002, 293: 463-469. 10.1016/S0006-291X(02)00238-3.PubMed CentralView ArticlePubMedGoogle Scholar
- Leyland-Jones B: Trastuzumab: hopes and realities. Lancet Oncol. 2002, 3: 137-144. 10.1016/S1470-2045(02)00676-9.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.